Nafeesa Naeem, Amina Sadiq, Gehan Ahmed Othman, Habab M. Yassin and Ehsan Ullah Mughal
RSC Adv., 2024,14, 35769-35970
From themed collection:
2024 Reviews in RSC Advances
Abstract
Heterocyclic compounds represent a prominent class of molecules with diverse pharmacological activities.
Wagdy M. Eldehna, Zainab M. Elsayed, Mohamed R. Elnagar, Andrea Ammara, Mahmoud S. Elkotamy, Rehan Monir, Alessio Nocentini, Mohammed M. Al-Sanea, Claudiu T. Supuran, Haytham O. Tawfik, Hatem A. Abdel-Aziz and Ahmed T. Negmeldin
RSC Med. Chem., 2026, Advance Article
Abstract
The overexpression of VEGFR-2 and carbonic anhydrase IX (hCA IX), two proven therapeutic targets in aggressive malignancies, is closely associated with hypoxia-driven tumor growth.
Fawzia F. Albelwi, Mohamed S. Nafie, Nader R. Albujuq, Wafa Hourani, Ateyatallah Aljuhani, Khaled M. Darwish, Mohamed M. Tawfik, Nadjet Rezki and Mohamed Reda Aouad
RSC Med. Chem., 2024,15, 2440-2461
Abstract
A novel synthesized chromene-1,2,3-triazole benzene sulfonamide exhibited potent apoptosis induction through carbonic anhydrase-IX inhibition against prostate cancer.
Virginia Pontecorvi, Andrea Angeli, Luigi Cutarella, Mattia Mori, Daniela Secci, Michele Coluccia, Simone Carradori, Anna Troiani, Federico Pepi, Chiara Salvitti, Alessia Di Noi, Mattia Spano, Francesca Arrighi, Elena De Falco, Antonella Bordin, Emanuela Berrino, Arianna Granese, Paola Chimenti, Paolo Guglielmi and Claudiu T. Supuran
RSC Med. Chem., 2025,16, 3603-3621
Abstract
Development of the novel coumalic acid-based selective hCA IX and XII inhibitors.
Amina Merabti, Darío Puchán Sánchez, Alessio Nocentini, Lamiaa M. A. Ali, Christophe Nguyen, Denis Durand, Kathleen Hamon, Tatiana Ghanem, Philippe Arnoux, Pierre Josse, Céline Frochot, Raivis Zalubovskis, Sébastien Richeter, Magali Gary-Bobo, Claudiu T. Supuran, Clément Cabanetos, Jean-Yves Winum and Sébastien Clément
Mater. Adv., 2024,5, 4172-4177
From themed collection:
Popular Advances
Abstract
A series of thiochromenocarbazole imide (TCI) photosensitizers featuring carbonic anhydrase inhibitors (CAi) was designed to alleviate the consequences of PDT-induced hypoxia by merging the advantages of hCA IX knockdowns with PDT.